person · Reporting owner
Nicholson Donald William
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.IRON · Entity 2273 | Director | June 18, 2026 | June 23, 2026 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 15, 2022 | June 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17 | Direct | 6,212 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
Kymera Therapeutics, Inc.
Report date June 15, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.18 · Expires 2032-06-14 | Direct | 12,000 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 12,000 · Balance 12,000 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date February 09, 2026 · Filed February 09, 2026
Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Other · Disposed 21,357 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 6,212 | $0.00 Strike: $70.79 | $0.00 |
DisclosureSEC source: 0001193125-26-279732 · ownership.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,212 Underlying: Common Stock · 6,212 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $33.20 | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · derivative · entry 7 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | Not disclosed Strike: $48.30 | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · derivative · entry 6 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 1,920 | Not disclosed Strike: $61.90 | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · derivative · entry 5 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,920 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 1,500 | Not disclosed Strike: $265.90 | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · derivative · entry 4 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 5,200 | Not disclosed Strike: $190.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · derivative · entry 3 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,200 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 3,000 | Not disclosed Strike: $3.87 | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · derivative · entry 2 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:39 UTC | Generation Bio Co. GBIO · Entity 67174 | OtherCommon Stock | 21,357 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-012193 · tm265471-8_4seq1.xml · nonDerivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:25 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $50.86 | $0.00 |
DisclosureSEC source: 0000950170-25-086385 · ownership.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-25-015962 · form4-06062025_040616.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073669 · ownership.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001415889-24-016180 · form4-06102024_040607.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 100,000 | $1.44 | $144,000.00 |
DisclosureSEC source: 0001415889-23-015856 · form4-12052023_041201.xml · nonDerivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,576 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 22:24 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 7,136 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0000899243-23-015270 · doc4.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,136 Underlying: Common Stock · 7,136 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2024 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:15 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001415889-23-009608 · form4-06122023_040611.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:22 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-23-000320 · doc4.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:06 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0000899243-22-022796 · doc4.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 19,200 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0001415889-22-006478 · form4-06132022_040617.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:53 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 8,126 | $4.71 | $38,273.46 |
DisclosureSEC source: 0001415889-22-002899 · form4-03112022_010348.xml · nonDerivative · entry 2 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,576 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.67 to $4.78, inclusive. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:53 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 2,293 | $4.79 | $10,983.47 |
DisclosureSEC source: 0001415889-22-002899 · form4-03112022_010348.xml · nonDerivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.78 to $4.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 20,063 | $0.00 Strike: $49.10 | $0.00 |
DisclosureSEC source: 0000899243-21-024448 · doc4.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,063 Underlying: Common Stock · 20,063 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:10 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $26.59 | $0.00 |
DisclosureSEC source: 0001415889-21-002952 · form4-06112021_010615.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:05 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 4,081 | $24.50 | $99,984.50 |
DisclosureSEC source: 0001415889-21-000311 · form4-01132021_010108.xml · nonDerivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,157 Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 22:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 40,127 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023242 · doc4.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,127 Underlying: Common Stock · 40,127 shares Expires 2030-08-19 F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:31 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries A Preferred Stock · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017106 · doc4.xml · derivative · entry 2 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:31 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionCommon Stock | 56,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017106 · doc4.xml · nonDerivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:28 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-016561 · doc4.xml · derivative · entry 1 Nicholson Donald William · CIK 0001814617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.